Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Antitumor Effects of Sacituzumab Govitecan Plus Platinum-Based Chemotherapy

Oncotarget

March 14, 2024
In this study, researchers investigated the antitumor effects of Sacituzumab govitecan in combination with platinum-based chemotherapy. continue reading »

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

News

March 6, 2024
PRESS RELEASE: On March 5, 2024, a new research paper was published in Oncotarget, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.” continue reading »

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

News

March 4, 2024
PRESS RELEASE: On February 22, 2024, a new research paper was published in Oncotarget, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.” continue reading »

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula

News

February 28, 2024
PRESS RELEASE: On February 22, 2024, a new research paper was published in Oncotarget, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.” continue reading »

GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells

News

February 26, 2024
PRESS RELEASE: On February 8, 2024, a new research paper was published in Oncotarget, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.” continue reading »